Interventions to enhance testing, linkage to care, and treatment initiation for hepatitis C virus infection: a systematic review and meta-analysis.


Journal

The lancet. Gastroenterology & hepatology
ISSN: 2468-1253
Titre abrégé: Lancet Gastroenterol Hepatol
Pays: Netherlands
ID NLM: 101690683

Informations de publication

Date de publication:
05 2022
Historique:
received: 26 08 2021
revised: 08 12 2021
accepted: 08 12 2021
pubmed: 19 3 2022
medline: 13 4 2022
entrez: 18 3 2022
Statut: ppublish

Résumé

Despite the goal set by WHO to eliminate hepatitis C virus (HCV) as a public health threat, uptake of HCV testing and treatment remains low. To achieve this target, evidence-based interventions are needed to address the barriers to care for people with, or at risk of, HCV infection. We aimed to assess the efficacy of interventions to improve HCV antibody testing, HCV RNA testing, linkage to HCV care, and treatment initiation. In this systematic review and meta-analysis, we searched MEDLINE (PubMed), Scopus, Web of Science, the Cochrane Central Register of Controlled Trials, and PsycINFO without language restrictions for reports published between database inception and July 21, 2020, assessing the following primary outcomes: HCV antibody testing; HCV RNA testing; linkage to HCV care; and direct-acting antiviral treatment initiation. We also searched key conference abstracts. We included randomised and non-randomised studies assessing non-pharmaceutical interventions that included a comparator or control group. Studies were excluded if they enrolled only paediatric populations (aged <18 years) or if they conducted the intervention in a different health-care setting to that of the control or comparator. Authors were contacted to clarify study details and to obtain additional population-level data. Data were extracted from the records identified into a pre-piloted and standardised data extraction form and a random-effects meta-analysis was used to pool the effects of the interventions on study outcomes. This study is registered in PROSPERO, CRD42020178035. Of 15 342 unique records identified, 142 were included, which reported on 148 unique studies (47 randomised controlled trials and 101 non-randomised studies). Medical chart reminders, provider education, and point-of-care antibody testing significantly improved at least three study outcomes compared with a comparator or control. Interventions that simplified HCV testing, including dried blood spot testing, point-of-care antibody testing, reflex RNA testing, and opt-out screening, significantly improved testing outcomes compared with a comparator or control. Enhanced patient and provider support through patient education, provider care coordination, and provider education also significantly improved testing outcomes compared with a comparator or control. Integrated care and patient navigation or care coordination significantly improved linkage to care and the uptake of direct-acting antiviral treatment compared with a comparator or control. Several interventions to improve HCV care that address several key barriers to HCV care were identified. New models of HCV care must be designed and implemented to address the barriers faced by the population of interest. Further high-quality research, including rigorously designed randomised studies, is still needed in key populations. None.

Sections du résumé

BACKGROUND
Despite the goal set by WHO to eliminate hepatitis C virus (HCV) as a public health threat, uptake of HCV testing and treatment remains low. To achieve this target, evidence-based interventions are needed to address the barriers to care for people with, or at risk of, HCV infection. We aimed to assess the efficacy of interventions to improve HCV antibody testing, HCV RNA testing, linkage to HCV care, and treatment initiation.
METHODS
In this systematic review and meta-analysis, we searched MEDLINE (PubMed), Scopus, Web of Science, the Cochrane Central Register of Controlled Trials, and PsycINFO without language restrictions for reports published between database inception and July 21, 2020, assessing the following primary outcomes: HCV antibody testing; HCV RNA testing; linkage to HCV care; and direct-acting antiviral treatment initiation. We also searched key conference abstracts. We included randomised and non-randomised studies assessing non-pharmaceutical interventions that included a comparator or control group. Studies were excluded if they enrolled only paediatric populations (aged <18 years) or if they conducted the intervention in a different health-care setting to that of the control or comparator. Authors were contacted to clarify study details and to obtain additional population-level data. Data were extracted from the records identified into a pre-piloted and standardised data extraction form and a random-effects meta-analysis was used to pool the effects of the interventions on study outcomes. This study is registered in PROSPERO, CRD42020178035.
FINDINGS
Of 15 342 unique records identified, 142 were included, which reported on 148 unique studies (47 randomised controlled trials and 101 non-randomised studies). Medical chart reminders, provider education, and point-of-care antibody testing significantly improved at least three study outcomes compared with a comparator or control. Interventions that simplified HCV testing, including dried blood spot testing, point-of-care antibody testing, reflex RNA testing, and opt-out screening, significantly improved testing outcomes compared with a comparator or control. Enhanced patient and provider support through patient education, provider care coordination, and provider education also significantly improved testing outcomes compared with a comparator or control. Integrated care and patient navigation or care coordination significantly improved linkage to care and the uptake of direct-acting antiviral treatment compared with a comparator or control.
INTERPRETATION
Several interventions to improve HCV care that address several key barriers to HCV care were identified. New models of HCV care must be designed and implemented to address the barriers faced by the population of interest. Further high-quality research, including rigorously designed randomised studies, is still needed in key populations.
FUNDING
None.

Identifiants

pubmed: 35303490
pii: S2468-1253(21)00471-4
doi: 10.1016/S2468-1253(21)00471-4
pii:
doi:

Substances chimiques

Antiviral Agents 0
RNA 63231-63-0

Types de publication

Journal Article Meta-Analysis Systematic Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

426-445

Subventions

Organisme : Medical Research Council
ID : MR/N00616X/1
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn
Type : ErratumIn

Informations de copyright

Copyright © 2022 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests JG is a consultant or adviser for, and has received research grants from, AbbVie, Camurus, Cepheid, Gilead Sciences, Hologic, Indivor, and Merck, and has received honoraria from AbbVie, Cepheid, Gilead Sciences, and Merck. GJD is a consultant or adviser for, and has received research grants from, AbbVie, Abbot Diagnostics, Gilead Sciences, Bristol Myers Squibb, Cepheid, GlaxoSmithKline, Merck, Janssen, and Roche. JWW is supported by The Task Force for Global Health, which receives funds for the general support of the Coalition for Global Hepatitis Elimination from Abbott, Gilead, AbbVie, Merck, Siemens, Cepheid, Roche, Pharco, Zydus-Cadila, governmental agencies, and philanthropic organisations. MH has received unrestricted honoraria and travel expenses from MSD and Gilead unrelated to the submitted work. PV has received research grants from Gilead Sciences and is in receipt of grants from the UK National Institute of Health Research. All other authors declare no competing interests. No input into this work was provided by any of the aforementioned listed organisations or institutions.

Auteurs

Evan B Cunningham (EB)

The Kirby Institute, UNSW Sydney, Sydney, NSW, Australia. Electronic address: ecunningham@kirby.unsw.edu.au.

Alice Wheeler (A)

The Kirby Institute, UNSW Sydney, Sydney, NSW, Australia.

Behzad Hajarizadeh (B)

The Kirby Institute, UNSW Sydney, Sydney, NSW, Australia.

Clare E French (CE)

Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK; National Institute for Health Research Health Protection Research Unit in Behavioural Science and Evaluation, University of Bristol, Bristol, UK.

Rachel Roche (R)

Blood Safety, Hepatitis, Sexually Transmitted Infections and HIV Division, National Infection Service, Public Health England Colindale, London, UK; National Institute for Health Research Health Protection Research Unit in Blood Borne and Sexually Transmitted Infections at UCL, National Institute for Health Research, London, UK.

Alison D Marshall (AD)

The Kirby Institute, UNSW Sydney, Sydney, NSW, Australia; Centre for Social Research in Health, UNSW Sydney, Sydney, NSW, Australia.

Guillaume Fontaine (G)

Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada; Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.

Anna Conway (A)

The Kirby Institute, UNSW Sydney, Sydney, NSW, Australia; Centre for Social Research in Health, UNSW Sydney, Sydney, NSW, Australia.

Braulio M Valencia (BM)

The Kirby Institute, UNSW Sydney, Sydney, NSW, Australia.

Sahar Bajis (S)

The Kirby Institute, UNSW Sydney, Sydney, NSW, Australia.

Justin Presseau (J)

Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.

John W Ward (JW)

Coalition for Global Hepatitis Elimination, The Task Force for Global Health, Decatur, GA, USA.

Louisa Degenhardt (L)

National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, NSW, Australia.

Gregory J Dore (GJ)

The Kirby Institute, UNSW Sydney, Sydney, NSW, Australia.

Matthew Hickman (M)

Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

Peter Vickerman (P)

Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

Jason Grebely (J)

The Kirby Institute, UNSW Sydney, Sydney, NSW, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH